Navigation Links
Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
Date:10/21/2009

PRINCETON, N.J., Oct. 21 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with an undisclosed client. According to the agreement, Laureate will develop the process to manufacture a unique Fc Fusion Protein and produce this product under cGMP conditions for use in clinical trials. Terms of the manufacturing agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"This project is a great fit with the experience that we have developed over the past few years working with fusion proteins," said Robert J. Broeze, Ph. D., President & CEO of Laureate Pharma. "We have had great success working with these unique protein products and are delighted to have the opportunity to help advance this product into the clinic."

"We are seeing a strong trend in the biopharmaceutical industry to develop fusion protein products with unique properties," commented Dan Leone, Vice President, Business Development of Laureate Pharma. "Along with monoclonal antibodies, manufacturing fusion proteins has become one of Laureate's core competencies."

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, NJ. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Dan Leone, Vice President, Business Development at 609-919-3300, or info@laureatepharma.com or visit www.laureatepharma.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Robert Broeze | https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=84360

SOURCE Laureate Pharma, Inc.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
2. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
3. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
4. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
8. ISTA Pharmaceuticals to Present at 2009 BIOCOM Investor Conference
9. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
10. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
11. Four Pharmaceutical Companies Pay $124 Million for Submission of False Claims to Medicaid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... May 23, 2016 Global Paclitaxel ... pages, profiles 12 companies and the Paclitaxel analysis in ... on the industry and its players. This ... in nature, details the current state of the industry ... definitions, classifications, applications and industry chain structure. The Paclitaxel ...
(Date:5/23/2016)... 2016 Clarifying Vision - Prospects ... and Vision Care What can be expected ... to grow at the fastest rates? This visiongain ... data, trends, opportunities and prospects. ,Our ... the most lucrative areas in the industry and the ...
(Date:5/23/2016)... May 23, 2016 Gamida Cell, ... treatment of cancer and orphan genetic diseases, announced today ... $4.4 million from the Israel Innovation Authority (formerly the ... of Economy and Industry. The mission of the Israel ... various industries, including science and technology, while stimulating economic ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... ... The University of San Francisco (USF) has named Margaret Wooding Baker dean ... more than 100 full-time faculty and staff, and serve as a member of the ... Baker comes to USF from the University of Washington in Seattle, where she is ...
(Date:5/25/2016)... FLA (PRWEB) , ... May 25, 2016 , ... ... technology to help turn back the hands of time of female aging. The ... and childbirth. Women with symptoms such as leakage, laxity, itchiness and pain have ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State ... Meeting for their work on visual evoked potential and human attention. The article, ... used the Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... builder, has announced that it will join America's leading engineers at the American ... held at the Georgia World Congress Center. , Engineers, speakers and exhibitors ...
(Date:5/24/2016)... ... May 24, 2016 , ... According to an article ... people randomly assigned to reduce the amount of calories they consumed by 25% experienced ... body weight enjoyed better sleep, improved quality of life, and enhanced sexual function compared ...
Breaking Medicine News(10 mins):